Re: Farmas USA
OncoGenex Pharma (OGXI) to Merge with Achieve Life Science
Upon completion of the proposed merger, Achieve's equity holders are expected to own 75% of the combined company's outstanding shares and current stockholders of OncoGenex are expected to own the remaining 25% of the combined company's outstanding shares. Following completion of the merger, OncoGenex Pharmaceuticals, Inc. will be renamed Achieve Life Sciences, Inc
http://www.streetinsider.com/
---
Mast Therapeutics And Savara Sign Merger Agreement
Prior to closing, Mast will seek stockholder approval to conduct a reverse split of its outstanding shares to satisfy listing requirements of the NYSE MKT. The combined company is expected to trade on the NYSE MKT under a new ticker symbol
http://www.prnewswire.com/news-releases/mast-therapeutics-and-savara-sign-merger-agreement-300387375.html